FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. - Wikidata - awgldk - TriplyDB

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.

http://www.wikidata.org/entity/Q33363249

about

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.Combination chemotherapy of heptaplatin, paclitaxel and 5-fluorouracil in patients with advanced gastric cancer: a pilot study.Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma Palliative chemotherapy for advanced gastric cancer.Weekly chemotherapy in advanced prostatic cancer Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.Chemotherapy for gastric cancer.Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer.A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer.Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Management of carcinomas of the upper gastrointestinal tract.Chemotherapy for advanced gastric cancer: review of global and Japanese status.Advanced gastric cancer: an update and future directions Evolution of preoperative and postoperative therapies in the management of localized gastroesophageal cancers.Chemotherapy for advanced gastric cancer: slow but further progress.Pre-operative chemotherapy for gastric cancer.Systemic therapy for advanced gastric cancer: a clinical practice guideline.Global chemotherapy development for gastric cancer.Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.Mitochondrial protein 18 (MTP18) plays a pro-apoptotic role in chemotherapy-induced gastric cancer cell apoptosis.Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.Implications of therapy-induced selective autophagy on tumor metabolism and survival.Curing gastric cancer--hone the scalpel with magic?Schedule-dependent combined sensitivity testing of anti-cancer agents in human gastric carcinoma cell lines.A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies.High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy.

P2860

Q33361500-B3B62380-0C75-4005-9E0B-CD069C331EE4 Q33366008-CF8E0625-1BAA-4943-B823-64E43EC82A2F Q33389160-E2D34CF2-C5D9-4EFD-9311-B758920BBBF5 Q33488159-BFB804AA-3540-45E7-8511-6A9143FCA690 Q33490610-63562291-3668-468B-8F7B-8E0F76E8A080 Q33503301-4AE51678-24E9-444C-B835-2B8E957D0A9A Q34852173-ED9895BB-9E3B-44FD-9413-70460D0CE202 Q35034753-43660E8D-5334-48B2-A092-9A0DF1C9CBEB Q35936039-3D2780F1-781B-498E-8900-CB36445C4817 Q35977021-82138C26-9BCF-4B21-BFAB-16F7B91FF0BE Q36292847-6487F09B-EFF3-471A-A6FF-36BB7EB01325 Q36398226-6A53695D-F7CF-4A1C-B11E-F301296C94FA Q36625990-4804E01A-B1B9-4565-9D87-A06C5DACAF79 Q36642170-E39A4C75-6E16-4063-9EFD-F1B9FF1A155A Q36644681-98CAD8FA-4A74-4BAF-BE73-119B6BED2063 Q36673543-B58AABED-1DC7-4748-B074-56D3B5C07649 Q36748415-E1F4C910-B28E-48E4-91CB-BCDD7145D8CB Q37076553-2E6ACFCE-75DD-471E-9B34-6F97110CB8DC Q37141665-FE67E5D5-FAB8-4868-A422-8E7D91DABC73 Q37141674-8E7A4387-F5C3-4D9C-B359-BFB19355E671 Q37446941-73AB5E72-D8FB-4524-BBE5-1ACA4511819B Q37636574-62D83102-9F85-41E1-A121-DAD6C3308EEA Q37923311-94D341CF-2F32-401C-8F40-EBBE88ED5226 Q38813532-465906B2-C9BB-4515-A9A7-B0DCC794BE6E Q41044387-F03BBDD0-E638-46A7-A06F-AEFC48CD0427 Q41345691-EB991255-DBBA-4159-A985-368EB7DC2B6F Q42285544-E473F1BB-52C6-415C-B1B7-5DEB1083E1A5 Q42541156-0015D77E-CE79-437A-9B4A-36DEB65B9B1B Q42715710-E80A361D-3B0A-4554-A8B7-055D21165D5A Q43686890-860872A1-C28E-48B9-99FA-4745059A8BF6 Q44180988-ABF06508-E534-4817-895B-BF752E91FC8A Q44258498-67BB222C-FDAF-4A0B-88F6-10230FC62259 Q45154773-ED6F66D1-F306-4FA9-932A-32CCBB3706EF Q53579494-51756559-E518-466B-A6FE-2FD2C7492EBF Q54139402-A1FBD294-27BF-4CFD-A4E4-353F7BC31BE1

P2860

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.

http://www.wikidata.org/entity/Q33363249

description

1992 nî lūn-bûn

@nan

1992 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1992 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1992年の論文

@ja

1992年論文

@yue

1992年論文

@zh-hant

1992年論文

@zh-hk

1992年論文

@zh-mo

1992年論文

@zh-tw

1992年论文

@wuu

name

FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.

@ast

FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.

@en

type

label

FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.

@ast

FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.

@en

prefLabel

FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.

@ast

FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.

@en

P1433

Q33363249-C61F0D76-C3A9-4612-AFE4-A8592F1AC145

P1476

Q33363249-1D1C29C1-EAA8-4CBB-B56B-CAE03EC7DC59

P2093

Q33363249-28D0FDBB-7DB9-4477-B3BE-FC639441CC08

Q33363249-40961C3B-112B-4D0E-B5D9-5EE6E27F075C

Q33363249-43E0464C-582B-4FAB-92D1-BB6ED60D4511

Q33363249-627A544E-BE82-4666-87B7-350017205DA0

Q33363249-6582F47A-E29B-4435-951A-FD5C831F74EF

Q33363249-93D0495B-8F51-4BB3-A01F-B236D60BB807

Q33363249-B73065FA-14A3-40BA-A578-7B469A30BECE

Q33363249-D861BCB0-FC80-4C60-910E-8A849F5D7D8C

Q33363249-EE5898C0-354F-44DE-9E15-79B1C0FA6C44

Q33363249-F945814F-C5C7-4AA7-90FF-B3AE706C49CC

P304

Q33363249-C737F657-14BB-40B1-B6D2-B71C6891224C

P31

Q33363249-36EFB14A-C874-4224-A5E6-15F1EACCA2D0

P356

Q33363249-997B9561-E860-43FE-99C3-C94D43A3FC49

P407

Q33363249-E11DA721-83B0-4510-A01D-D77BE944182B

P433

Q33363249-29309406-6FD5-4BCC-9FAA-0CDCECE45E93

P478

Q33363249-7A92053F-BECD-49BE-B4EF-F6CB4AEC04D0

P577

Q33363249-1003984D-0D33-4FCA-B301-B8DE291BCB19

P698

Q33363249-A81F25F4-A30C-461D-A1FA-5F096E0BF6CE

P356

JCO.1992.10.4.541

P1433

Journal of Clinical Oncology

P1476

FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.

@en

P2093

C Lightdale

http://www.w3.org/2001/XMLSchema#string

D Chapman

http://www.w3.org/2001/XMLSchema#string

D Ginn

http://www.w3.org/2001/XMLSchema#string

D Kelsen

http://www.w3.org/2001/XMLSchema#string

D Niedzwiecki

http://www.w3.org/2001/XMLSchema#string

L Saltz

http://www.w3.org/2001/XMLSchema#string

M Brennan

http://www.w3.org/2001/XMLSchema#string

O T Atiq

http://www.w3.org/2001/XMLSchema#string

R Heelan

http://www.w3.org/2001/XMLSchema#string

V Vinciguerra

http://www.w3.org/2001/XMLSchema#string

P304

541-548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.1992.10.4.541

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

1992-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1548519

http://www.w3.org/2001/XMLSchema#string